INFORMATION DISCLOSURE	Application Number		10551847	
	Filing Date		2006-06-23	
	First Named Inventor HAIXI		IANG, LIN	
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		1648	
(Not for submission under 57 Of it 1.55)	Examiner Name	LE, E	EMILY M	
	Attorney Docket Numb	er	NBMP-001(SP)	

				U.S.I	PATENTS	Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	3692899		1972-09-19	Levy, H.	
	2	3906092		1975-09-16	Hilleman, M., et al.	
	3	4082735		1978-04-04	Jones, G., et al.	
	4	4082736		1978-04-04	Jones, G., et al.	
	5	4094971		1978-06-13	Chedid, L., et al.	
	6	4101536		1978-07-18	Yamamura, Y., et al.	
	7	4124702		1978-11-07	Lampson, G., et al.	
	8	4153684		1979-05-08	Audibert, F., et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10551847		
Filing Date		2006-06-23		
First Named Inventor HAIXI		ANG, LIN		
Art Unit		1648		
Examiner Name LE, El		MILY M		
Attorney Docket Number		NBMP-001(SP)		

	9	4185089		1980-01-22	Derrien, M., et al.	
	10	4186194		1980-01-29	Adam, A., et al.	
	11	4235771		1980-11-25	Adam, A., et al.	
	12	4314998		1982-02-09	Yamamura, Y., et al.	
	13	4323559		1982-04-06	Audibert, F., et al.	
	14	4327085		1982-04-27	Audibert, F., et al.	
	15	4369178		1983-01-18	Yamamura, Y., et al.	
	16	6008200		1999-28-12	Krieg, A., et al.	
If you wish	h to ac	dd additional U.S. Paten	t citatio	n information pl	ease click the Add button.	Add
			U.S.P	ATENT APPLIC	CATION PUBLICATIONS	Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20070166800	A1	2007-07-19	HAIXIANG, L.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10551847		
Filing Date		2006-06-23		
First Named Inventor HAIXI		ANG, LIN		
Art Unit		1648		
Examiner Name	LE, E	MILY M		
Attorney Docket Number		NBMP-001(SP)		

			_				,				
	2	20070166239	A1	2007-07	'-19	HAIXIANG, L.					
If you wish	If you wish to add additional U.S. Published Application citation information please click the Add button. Add										
FOREIGN PATENT DOCUMENTS Remove											
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j		Kind Code ⁴	Publication	Applicant of cited Wh		where Rel Passages	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1	JP01093540	JP		A2	1989-04-12	Mount Sinai Hospita	al Corp			
If you wish	n to ac	dd additional Foreign Pa	atent Do	cument	citation	information pl	ease click the Add	button	Add		
			NON	I-PATEN	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.								T5	
	1	ELLOUZ, F., et al. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochemical and Biophysical Research Communications. 1974, vol. 59, no. 4, pp. 1317-1325.									
	2	GUPTA, R. K., et al. Adjuvants for human vaccines - current status, problems and future prospects. Vaccine. 1995, vol. 13, no. 14, pp. 1263-1278.									
	3	GUPTA, R. K., et al. Adjuvants - a balance between toxicity and adjuvanticity. Vaccine. 1993, vol. 11, pp. 293-306.									
	4	KANZLER, H., et al. Therapeutic targeting of innate immunity with toll-like receptor agonists and antagonists. Nature Medicine. 2007, vol. 13, no. 5, pp 552-559. E-pub 3 May 2007.									
	5	KENNEY, R. T., et al. Meeting report, 2nd meeting on novel adjuvants currently in/close to human clinical testing, World Health Organization - Organization Mondiale de la Sante, Fondation Merieux, Annecy, France, 5-7 June 2000. Vaccine. 2002, vol. 20, pp. 2155-2163.									

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10551847		
Filing Date		2006-06-23		
First Named Inventor HAIXI		ANG, LIN		
Art Unit		1648		
Examiner Name	LE, E	MILY M		
Attorney Docket Number		NBMP-001(SP)		

	6		RAHAN, P. S., et al. Antiviral activity and side effects of polyriboinosinic-cytidylic cular size. Proceedings of the National Academy of Sciences USA. 1972, vol. 6						
	7	NORLUND, J. J., et al. Inhibition of biologic activity of Poly I: Poly C by human plasma (34492). Proc Soc Exp Biol Med. 1970, vol. 133, pp. 439-444.							
	8		PHILLIPS, B. M., et al. Systemic toxicity of polyinosinic acid: polycytidylic acid in rodents and dogs. Toxicology and Applied Pharmacology. 1971, vol. 18, pp. 220-230.						
	9	SELA	SELA, M. Antigenicity: some molecular aspects. Science. 1969, vol. 166, pgs. 1365-1374.						
	10	STERN, R. A nuclease from animal serum which hydrolyzes double-stranded RNA. Biochemical and Biophysical Research Communications. 1970, vol. 41, no. 3, pp. 608-614.							
	11	WRIGHT, C. L., et al. The adjuvant effects mycoviral dsRNA and polyinosinic:polycytidylic acid on the murine immune response. Biochemical and Biophysical Research Communications. 1985, vol. 131, no. 2, pp. 949-955.							
If you wis	h to ac	ld add	ditional non-patent literature document citation information please click	the Add b	utton Add				
			EXAMINER SIGNATURE						
Examiner	Examiner Signature Date Considered								
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									
¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.									